UP TO ~$214M POTENTIAL ~$18.5M BASE PERIOD
$214M Potential BARDA
funding, SCY-247
Clinical-stage · Rare disease

Two rare-disease
programs. One new
BARDA contract.

Up to ~$214M if all options are exercised, for investigational antifungal SCY-247.

SCY-770 AMPK mTOR cAMP
~140K Diagnosed U.S.
ADPKD patients
SCY-770 · Investigational

A direct AMPK
activator for a
rare kidney disease.

Orphan-designated. Phase 2 proof-of-concept in ADPKD planned to start Q4 2026.

ORAL IV FUNGAL CELL
Oral+IV Two formulations
in development
SCY-247 · Investigational

A new-class
antifungal for
invasive infections.

FDA Orphan, QIDP and Fast Track designations. IV Phase 1 dosing complete.

SCY-770 PHASE 1 PHASE 2 · Q4 2026 SCY-247 PHASE 1 PHASE 2 · PLANNED
Q4 2026 SCY-770 Phase 2
planned start
What's next

Two programs
moving toward
Phase 2.

$71.1M in cash and investments at Jun 30, 2026; runway expected into 2029.

SCYNEXIS
INVESTOR RELATIONS · NASDAQ: SCYX
$214M Potential BARDA funding
2029 Expected cash runway
You're subscribed. Watch your inbox.

By subscribing, you consent to receive investor-related emails from SCYNEXIS, Inc. You can unsubscribe at any time. Privacy policy

SCY-770 & SCY-247 are investigational, not FDA-approved. Forward-looking statements: BARDA options, runway, timing.